Literature DB >> 29496987

18F-XTRA PET for Enhanced Imaging of the Extrathalamic α4β2 Nicotinic Acetylcholine Receptor.

Jennifer M Coughlin1,2, Stephanie Slania3, Yong Du2, Hailey B Rosenthal2, Wojciech G Lesniak2, Il Minn2, Gwenn S Smith1,2, Robert F Dannals2, Hiroto Kuwabara2, Dean F Wong1,2,4,5, Yuchuan Wang2, Andrew G Horti2, Martin G Pomper6,2,3.   

Abstract

Reduced density of the α4β2 nicotinic acetylcholine receptor (α4β2-nAChR) in the cortex and hippocampus of the human brain has been reported in aging and patients with neurodegenerative disease. This study assessed the pharmacokinetic behavior of 18F-(-)-JHU86428 (18F-XTRA), a new radiotracer for in vivo PET imaging of the α4β2-nAChR, particularly in extrathalamic regions of interest in which the α4β2-nAChR is less densely expressed than in thalamus. 18F-XTRA was also used to evaluate the α4β2-nAChR in the hippocampus in human aging.
Methods: Seventeen healthy nonsmoker adults (11 men, 6 women; age, 30-82 y) underwent PET neuroimaging over 90 or 180 min in a high-resolution research tomograph after bolus injection of 18F-XTRA. Methods to quantify binding of 18F-XTRA to the α4β2-nAChR in the human brain were compared, and the relationship between age and binding in the hippocampus was tested.
Results: 18F-XTRA rapidly entered the brain, and time-activity curves peaked within 10 min after injection for extrathalamic regions and at approximately 70 min in the thalamus. The 2-tissue-compartment model (2TCM) predicted the regional time-activity curves better than the 1-tissue-compartment model, and total distribution volume (VT) was well identified by the 2TCM in all ROIs. VT values estimated using Logan analysis with metabolite-corrected arterial input were highly correlated with those from the 2TCM in all regions, and values from 90-min scan duration were on average within 5% of those values from 180 min of data. Parametric images of VT were consistent with the known distribution of the α4β2-nAChR across the brain. Finally, an inverse correlation between VT in the hippocampus and age was observed.
Conclusion: Our results extend support for use of 18F-XTRA with 90 min of emission scanning in quantitative human neuroimaging of the extrathalamic α4β2-nAChR, including in studies of aging.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-XTRA; PET imaging; healthy aging; nicotinic acetylcholine receptor

Mesh:

Substances:

Year:  2018        PMID: 29496987      PMCID: PMC6167533          DOI: 10.2967/jnumed.117.205492

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  30 in total

Review 1.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

2.  First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine.

Authors:  Osama Sabri; Georg-Alexander Becker; Philipp M Meyer; Swen Hesse; Stephan Wilke; Susanne Graef; Marianne Patt; Julia Luthardt; Gudrun Wagenknecht; Alexander Hoepping; René Smits; Annegret Franke; Bernhard Sattler; Bernd Habermann; Petra Neuhaus; Steffen Fischer; Solveig Tiepolt; Winnie Deuther-Conrad; Henryk Barthel; Peter Schönknecht; Peter Brust
Journal:  Neuroimage       Date:  2015-05-30       Impact factor: 6.556

Review 3.  Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia.

Authors:  N D Volkow; Y S Ding; J S Fowler; S J Gatley
Journal:  Biol Psychiatry       Date:  2001-02-01       Impact factor: 13.382

4.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

5.  Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches.

Authors:  A Wevers; L Burghaus; N Moser; B Witter; O K Steinlein; U Schütz; B Achnitz; U Krempel; S Nowacki; K Pilz; J Stoodt; J Lindstrom; R A De Vos; E N Jansen Steur; H Schröder
Journal:  Behav Brain Res       Date:  2000-08       Impact factor: 3.332

Review 6.  Neuronal nicotinic receptors in the human brain.

Authors:  D Paterson; A Nordberg
Journal:  Prog Neurobiol       Date:  2000-05       Impact factor: 11.685

Review 7.  Recent PET radioligands with optimal brain kinetics for imaging nicotinic acetylcholine receptors.

Authors:  Andrew G Horti; Hiroto Kuwabara; Daniel P Holt; Robert F Dannals; Dean F Wong
Journal:  J Labelled Comp Radiopharm       Date:  2013 Mar-Apr       Impact factor: 1.921

8.  Imaging α4β2 Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [18F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions.

Authors:  Hiroto Kuwabara; Yongjun Gao; Michael Stabin; Jennifer Coughlin; Sridhar Nimmagadda; Robert F Dannals; Martin G Pomper; Andrew G Horti
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

Review 9.  Acetylcholine receptors in dementia and mild cognitive impairment.

Authors:  Osama Sabri; Kai Kendziorra; Henrike Wolf; Hermann-Josef Gertz; Peter Brust
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

10.  Clinical Perspective and Recent Development of PET Radioligands for Imaging Cerebral Nicotinic Acetylcholine Receptors.

Authors:  Andrew G Horti; Dean F Wong
Journal:  PET Clin       Date:  2009-01-01
View more
  3 in total

Review 1.  Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy.

Authors:  Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-13       Impact factor: 4.147

Review 2.  Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO.

Authors:  Vidya Narayanaswami; Kenneth Dahl; Vadim Bernard-Gauthier; Lee Josephson; Paul Cumming; Neil Vasdev
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

Review 3.  Current radiotracers to image neurodegenerative diseases.

Authors:  Solveig Tiepolt; Marianne Patt; Gayane Aghakhanyan; Philipp M Meyer; Swen Hesse; Henryk Barthel; Osama Sabri
Journal:  EJNMMI Radiopharm Chem       Date:  2019-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.